Background

• Specialty medications are complex therapies with stringent requirements for access, on treatment safety monitoring, and optimization to achieve therapeutic outcomes.
• The specialty medication market’s rapid expansion outpaces medication access and care coordination, leading many health systems to establish specialty pharmacies to address this growing care gap.
• With the health system specialty pharmacy (HSSP) model, pharmacists are integrated within health systems where they can access electronic health records (EHRs) and work closely with providers to provide comprehensive, patient-centered care leading to better clinical outcomes and financial benefits to patients, payers, and the health system.
• The Routine Assessment of Patient Index Data 3 (RAPID3) is a validated patient-reported outcome measure survey recommended by the American College of Rheumatology to assess disease activity and quality of life for patients with rheumatic disease.
• The hemoglobin A1c test estimates a patient’s average blood glucose over the previous three months.3 For patients with type 2 diabetes, a 1% reduction in A1c equates to diabetes-related total healthcare cost savings of $736 per year.
  

Objectives

• To quantify a HSSP’s impact on patient engagement and clinical outcomes
• To identify best practices for HSSPs in designing an effective specialty pharmacy program

Read the Outcomes Study by submitting the form below.

​